Type I Interferon Drives a Cellular State Inert to TCR‐Stimulation and Could Impede Effective T‐Cell Differentiation in Cancer
European Journal of Immunology · 2025
DOI: 10.1002/eji.202451371 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Immunology, 2025. Verfasst von Dillon Corvino und 18 weiteren Autor:innen. Beteiligte Einrichtung: Tumor-Immunobiology, Institute for Experimental Oncology, University Hospital Bonn, Bonn, Germany. Hauptthemen laut MEDLINE: CD8-Positive T-Lymphocytes, Interferon Type I, Lymphocytes, Tumor-Infiltrating, Head and Neck Neoplasms. Die Arbeit nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Forschungsgemeinschaft (DFG, German Research Foundation), DFG Excellence Strategy, Melanoma Research Alliance.
Abstract (Originalsprache)
Background
Head and neck squamous cell carcinoma (HNSCC) is linked to human papillomavirus (HPV) infection. HPV‐positive and HPV‐negative HNSCC exhibit distinct molecular and clinical characteristics. Although checkpoint inhibitors have shown efficiency in recurrent/metastatic HNSCC, response variability persists regardless of HPV status. This study aimed to explore the CD8 + T‐cell landscape in HPV‐negative HNSCC.
Methods
We performed simultaneous single‐cell RNA and TCR sequencing of CD8 + tumor‐infiltrating lymphocytes (TILs) from treatment‐naïve HPV‐negative HNSCC patients. Additionally, cells were stimulated ex vivo, which allowed for the tracking of clonal transcriptomic responses.
Results
Our analysis identified a subset of CD8 + TILs highly enriched for interferon‐stimulated genes (ISG). TCR analysis revealed ISG cells are clonally related to a population of granzyme K (GZMK)‐expressing cells. However, unlike GZMK cells, which exhibited rapid effector‐like phenotypes following stimulation, ISG cells were transcriptionally inert. Additionally, ISG cells showed specific enrichment within tumor and were found across multiple tumor entities.
Conclusions
ISG‐enriched CD8 + TILs are a consistent feature of various tumor entities. These cells are poorly understood but possess characteristics that may impact antitumor immunity. Understanding the unique properties and functionality of ISG cells could offer innovative treatment approaches to improve patient outcomes in HPV‐negative HNSCC and other cancer types.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Tumor-Immunobiology, Institute for Experimental Oncology, University Hospital Bonn, Bonn, Germany.
- Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia.
- Faculty of Medicine, University of Queensland, Brisbane, Queensland, Australia.
- QIMR Berghofer Medical Research Institute, Herston, Australia.
- Faculty of Mathematics and Natural Sciences, and the Life and Medical Sciences Institute (LIMES), Rheinische Friedrich-Wilhelms-Universität Bonn, Bonn, Germany.
- Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri, USA.
ORCID-Profile: Dillon Corvino, Tim Kempchen, Nazhifah Salim
Förderung
- Deutsche Forschungsgemeinschaft (DFG, German Research Foundation)
- DFG Excellence Strategy
- Melanoma Research Alliance
Zitieren
APA
Corvino, D., Batstone, M., Hughes, B. G. M., Kempchen, T., Ng, S. S., Salim, N., Schneppenheim, F., Rommel, D., Kumar, A., Pearson, S., Madore, J., Koufariotis, L. T., Steinheuer, L. M., Pathirana, D., Thurley, K., Hölzel, M., Borcherding, N., Braun, M., & Bald, T. (2025). Type I Interferon Drives a Cellular State Inert to TCR‐Stimulation and Could Impede Effective T‐Cell Differentiation in Cancer. European Journal of Immunology. https://doi.org/10.1002/eji.202451371
Vancouver
Corvino D, Batstone M, Hughes BGM, Kempchen T, Ng SS, Salim N, et al. Type I Interferon Drives a Cellular State Inert to TCR‐Stimulation and Could Impede Effective T‐Cell Differentiation in Cancer. European Journal of Immunology. 2025. doi:10.1002/eji.202451371
BibTeX
@article{Corvino2025,
author = {Corvino, Dillon and Batstone, Martin and Hughes, Brett G M and Kempchen, Tim and Ng, Susanna S and Salim, Nazhifah and Schneppenheim, Franziska and Rommel, Denise and Kumar, Ananthi and Pearson, Sally and Madore, Jason and Koufariotis, Lambross T and Steinheuer, Lisa Maria and Pathirana, Dilan and Thurley, Kevin and Hölzel, Michael and Borcherding, Nicholas and Braun, Matthias and Bald, Tobias},
title = {Type I Interferon Drives a Cellular State Inert to TCR‐Stimulation and Could Impede Effective T‐Cell Differentiation in Cancer},
journal = {European Journal of Immunology},
year = {2025},
doi = {10.1002/eji.202451371}
}
EUVIMED